All In Biotech

Drug Trial Radar · NCT01067521

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design

Last checked: Nov 20, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,404

Actual

Start

Jun 22, 2010

Primary completion

May 8, 2012

Study completion May 12, 2017

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to assess the efficacy of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in subjects with RRMS, as measured by the number of confirmed relapses during the 12 month placebo controlled period. The study has two periods: * Placebo Controlled Period: 12 months of 40 mg administered three times a week by subcutaneous injection or matching placebo. * Open Label Extension Period: All subjects will continue treatment with GA 40 mg administered three times a week, until this dose strength is commercially available for the treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the development of this GA dose regimen is stopped by the Sponsor

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • Glatiramer acetate (GA)Drug

    GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.

  • PlaceboDrug

    Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial RegressionTime frame: Day 1 to 12 months
  2. Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial RegressionTime frame: Day 1 up to 6.5 years

Locations

176 sites in 17 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 1332

    Birmingham, Alabama

  • Teva Investigational Site 1327

    Gilbert, Arizona

  • Teva Investigational Site 1311

    Phoenix, Arizona

  • Teva Investigational Site 1326

    Fullerton, California

  • Teva Investigational Site 1335

    La Jolla, California

  • Teva Investigational Site 1297

    Aurora, Colorado

  • Teva Investigational Site 1344

    Boulder, Colorado

  • Teva Investigational Site 1315

    Centennial, Colorado

  • Teva Investigational Site 1350

    Fort Collins, Colorado

  • Teva Investigational Site 1345

    Miami, Florida

  • Teva Investigational Site 1336

    Naples, Florida

  • Teva Investigational Site 1347

    Pompano Beach, Florida

  • Teva Investigational Site 1319

    Ponte Vedra, Florida

  • Teva Investigational Site 1298

    Sarasota, Florida

  • Teva Investigational Site 1316

    Sarasota, Florida

  • Teva Investigational Site 1340

    Tampa, Florida

  • Teva Investigational Site 1317

    Vero Beach, Florida

  • Teva Investigational Site 1303

    Northbrook, Illinois

  • Teva Investigational Site 1334

    Lenexa, Kansas

  • Teva Investigational Site 1302

    Lexington, Kentucky

  • Teva Investigational Site 1322

    Shreveport, Louisiana

  • Teva Investigational Site 1306

    Detroit, Michigan

  • Teva Investigational Site 1329

    Akron, Ohio

  • Teva Investigational Site 1349

    Columbus, Ohio

  • Teva Investigational Site 1313

    Dayton, Ohio

  • Teva Investigational Site 1318

    Uniontown, Ohio

  • Teva Investigational Site 1341

    Oklahoma City, Oklahoma

  • Teva Investigational Site 1310

    Nashville, Tennessee

  • Teva Investigational Site 1321

    Lubbock, Texas

  • Teva Investigational Site 1337

    Round Rock, Texas

  • Teva Investigational Site 1301

    San Antonio, Texas

  • Teva Investigational Site 1346

    San Antonio, Texas

  • Teva Investigational Site 1343

    Salt Lake City, Utah

  • Teva Investigational Site 1338

    Richmond, Virginia

  • Teva Investigational Site 1339

    Roanoke, Virginia

  • Teva Investigational Site 1300

    Vienna, Virginia

  • Teva Investigational Site 1323

    Kirkland, Washington

  • Teva Investigational Site 5940

    Blagoevgrad, Bulgaria

  • Teva Investigational Site 5931

    Pleven, Bulgaria

  • Teva Investigational Site 5932

    Pleven, Bulgaria

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.